S&P 500   5,254.28 (+0.11%)
DOW   39,750.83 (-0.02%)
QQQ   444.52 (-0.07%)
AAPL   170.86 (-1.41%)
MSFT   421.53 (+0.02%)
META   489.96 (-0.79%)
GOOGL   150.73 (-0.09%)
AMZN   181.07 (+0.69%)
TSLA   177.62 (-1.23%)
NVDA   907.51 (+0.56%)
NIO   4.60 (-1.50%)
AMD   181.89 (+1.28%)
BABA   72.45 (+1.20%)
T   17.57 (+0.11%)
F   13.21 (+1.15%)
MU   118.60 (-0.45%)
CGC   9.27 (-2.93%)
GE   174.72 (-3.00%)
DIS   122.63 (+1.36%)
AMC   3.77 (-13.13%)
PFE   27.91 (+0.47%)
PYPL   66.85 (+0.42%)
XOM   115.41 (+0.38%)
S&P 500   5,254.28 (+0.11%)
DOW   39,750.83 (-0.02%)
QQQ   444.52 (-0.07%)
AAPL   170.86 (-1.41%)
MSFT   421.53 (+0.02%)
META   489.96 (-0.79%)
GOOGL   150.73 (-0.09%)
AMZN   181.07 (+0.69%)
TSLA   177.62 (-1.23%)
NVDA   907.51 (+0.56%)
NIO   4.60 (-1.50%)
AMD   181.89 (+1.28%)
BABA   72.45 (+1.20%)
T   17.57 (+0.11%)
F   13.21 (+1.15%)
MU   118.60 (-0.45%)
CGC   9.27 (-2.93%)
GE   174.72 (-3.00%)
DIS   122.63 (+1.36%)
AMC   3.77 (-13.13%)
PFE   27.91 (+0.47%)
PYPL   66.85 (+0.42%)
XOM   115.41 (+0.38%)
S&P 500   5,254.28 (+0.11%)
DOW   39,750.83 (-0.02%)
QQQ   444.52 (-0.07%)
AAPL   170.86 (-1.41%)
MSFT   421.53 (+0.02%)
META   489.96 (-0.79%)
GOOGL   150.73 (-0.09%)
AMZN   181.07 (+0.69%)
TSLA   177.62 (-1.23%)
NVDA   907.51 (+0.56%)
NIO   4.60 (-1.50%)
AMD   181.89 (+1.28%)
BABA   72.45 (+1.20%)
T   17.57 (+0.11%)
F   13.21 (+1.15%)
MU   118.60 (-0.45%)
CGC   9.27 (-2.93%)
GE   174.72 (-3.00%)
DIS   122.63 (+1.36%)
AMC   3.77 (-13.13%)
PFE   27.91 (+0.47%)
PYPL   66.85 (+0.42%)
XOM   115.41 (+0.38%)
S&P 500   5,254.28 (+0.11%)
DOW   39,750.83 (-0.02%)
QQQ   444.52 (-0.07%)
AAPL   170.86 (-1.41%)
MSFT   421.53 (+0.02%)
META   489.96 (-0.79%)
GOOGL   150.73 (-0.09%)
AMZN   181.07 (+0.69%)
TSLA   177.62 (-1.23%)
NVDA   907.51 (+0.56%)
NIO   4.60 (-1.50%)
AMD   181.89 (+1.28%)
BABA   72.45 (+1.20%)
T   17.57 (+0.11%)
F   13.21 (+1.15%)
MU   118.60 (-0.45%)
CGC   9.27 (-2.93%)
GE   174.72 (-3.00%)
DIS   122.63 (+1.36%)
AMC   3.77 (-13.13%)
PFE   27.91 (+0.47%)
PYPL   66.85 (+0.42%)
XOM   115.41 (+0.38%)
OTCMKTS:MAQAF

Atlas Arteria (MAQAF) Stock Price, News & Analysis

$3.50
0.00 (0.00%)
(As of 03/27/2024 ET)
Today's Range
$3.50
$3.50
50-Day Range
$3.32
$3.85
52-Week Range
$3.25
$4.56
Volume
N/A
Average Volume
4,328 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
2.37%
Price Target
N/A
MAQAF stock logo

About Atlas Arteria Stock (OTCMKTS:MAQAF)

Atlas Arteria Limited owns, develops, and operates toll roads. It holds a 31.14% of interest in the APRR and A79 and 31.17% interest in the ADELAC located in France; 100% interest in the Warnow Tunnel located in Rostock, Germany; 66.67% interest in the Chicago Skyway situated in Chicago and 100% interest in the Dulles Greenway located in Virginia, United States. The company was formerly known as Macquarie Atlas Roads Limited and changed its name to Atlas Arteria Limited in May 2018. Atlas Arteria Limited was incorporated in 2009 and is based in Melbourne, Australia.

MAQAF Stock Price History

MAQAF Stock News Headlines

Atlas Arteria Ltd's Dividend Analysis
The AI Defense Stock Set to Soar
To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.
Macquarie Reaffirms Their Hold Rating on Atlas Arteria (MAQAF)
Atlas Arteria Ltd MAQAF
Buy Friday, Sell Monday, No Exceptions
Every week traders grind it out Monday through Friday… But neglect trading Friday to Monday… Or… “over the weekend” As one professional trader explains, trading over the weekend is one of the most forgiving strategies you can use today. It allows him to sidestep a lot of the midweek volatility. Yet, gives him the opportunity to target some of the markets biggest stock moves. Just recently, he posted a trade on Nordstrom… The trade was published at 3pm on a Friday afternoon and by Monday morning the trade more than doubled.
Atlas Arteria (MAQAF) Receives a Hold from RBC Capital
Bullish Atlas Arteria Insiders Loaded Up On AU$1.3m Of Stock
MAQAF - Atlas Arteria Limited
RBC Capital Sticks to Its Hold Rating for Atlas Arteria (MAQAF)
RBC Capital Sticks to Their Hold Rating for Atlas Arteria (MAQAF)
RBC Capital Reaffirms Their Buy Rating on Atlas Arteria (MAQAF)
Atlas Arteria Full Year 2022 Earnings: Misses Expectations
Atlas Arteria to bypass EastLink sale
ABN Amro Reaffirms Their Hold Rating on Atlas Arteria (MAQAF)
Positive Report for Atlas Arteria (MAQAF) from RBC Capital
See More Headlines
Receive MAQAF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Atlas Arteria and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Infrastructure Operations
Sub-Industry
N/A
Current Symbol
OTCMKTS:MAQAF
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Graeme Francis Bevans (Age 66)
    MD, CEO & Executive Director
    Comp: $1.83M
  • Mr. David Collins
    Chief Financial Officer
  • Mr. Vincent Portal-Barrault
    Chief Operating Officer
  • Tess Palmer
    Director of Investor Relations
  • Mr. Clayton John McCormack B.Com.
    L.L.B., Company Secretary & General Counsel
  • Navleen Prasad
    Public Affairs Manager
  • Jim Dickson
    Corporate Development & Strategy Executive
  • Ms. Catherine Brain
    Group Executive of People & Culture
  • Mr. Paul Lynch B.Com.
    L.L.B., Joint Company Secretary
  • Mr. Ryan Reynolds C.F.A.
    Specialist of Forecasting and Analysis

MAQAF Stock Analysis - Frequently Asked Questions

Should I buy or sell Atlas Arteria stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Atlas Arteria in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" MAQAF shares.
View MAQAF analyst ratings
or view top-rated stocks.

How have MAQAF shares performed in 2024?

Atlas Arteria's stock was trading at $3.95 on January 1st, 2024. Since then, MAQAF stock has decreased by 11.4% and is now trading at $3.50.
View the best growth stocks for 2024 here
.

Is Atlas Arteria a good dividend stock?

Atlas Arteria (OTCMKTS:MAQAF) pays an annual dividend of $0.08 per share and currently has a dividend yield of 5.02%. MAQAF has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer.

How do I buy shares of Atlas Arteria?

Shares of MAQAF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:MAQAF) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners